Cell Therapy Catapult Appoints Main Contractor for Manufacturing Centre
News Oct 10, 2015
The Cell Therapy Catapult has appointed M+W Group to construct its £55 million large-scale GMP manufacturing centre in Stevenage, UK.
M+W Group, whose UK headquarters are in Chippenham, Wiltshire, UK has been appointed following a comprehensive Official Journal of the European Union (OJEU) compliant tendering process. Planning permission was granted by Stevenage Borough Council on 18 August 2015.
The manufacturing centre is scheduled to open in 2017 and will be managed by the Cell Therapy Catapult. It will be used to manufacture products for late phase clinical trials and commercial supply of advanced therapeutic medicinal products, including cell and gene therapies.
The facility is expected to create up to 150 jobs and its position on the Stevenage Bioscience Catalyst campus will support SME biotech and life sciences companies based in the UK, complement the country’s existing capability and attract additional inward investment from global companies.
Keith Thompson, CEO, the Cell Therapy Catapult, said: “I am delighted that we will be working with M+W Group to create a centre that will advance industry in the UK to become a world leader in cell and gene therapy development and commercialization. The manufacturing centre will provide global scientific and medical communities with the assistance they need to convert research into products that have the potential to have a direct impact in advanced healthcare.”
Spencer Baber, Managing Director M+W Group UK said: “M+W Group is a specialist contractor for the construction of state-of-the-art facilities within the life sciences sector. We are proud to be associated with a government funded project of this specific nature which will see the UK established as the leading centre for the development of new and innovative medicinal products for the treatment of debilitating diseases such as blindness, diabetes and cancer. We are delighted to be selected as the Cell Therapy Catapult’s chosen partner in the delivery of this vision.”
In its 2013 survey of the UK’s manufacturing capability, the Cell Therapy Catapult identified Manufacturing and Supply Chain as one of the barriers to the translation of research into commercially viable products. The UK is strongly positioned for early clinical phase manufacturing and the large-scale GMP manufacturing centre will help grow a UK based global industry that will have a direct impact in healthcare.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE